MUSCLE RELAXANT AND ANALGESIC CAPLETS TABLET

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

IBUPROFEN; METHOCARBAMOL

Tilgængelig fra:

INTERNATIONAL PHARMACEUTICAL GENERICS LTD

ATC-kode:

M03BA53

INN (International Name):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

Dosering:

200MG; 500MG

Lægemiddelform:

TABLET

Sammensætning:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

Indgivelsesvej:

ORAL

Enheder i pakken:

100

Recept type:

OTC

Terapeutisk område:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

Produkt oversigt:

Active ingredient group (AIG) number: 0248961001; AHFS:

Autorisation status:

CANCELLED PRE MARKET

Autorisation dato:

2017-06-13

Produktets egenskaber

1 | P a g e
PRODUCT MONOGRAPH
MUSCLE RELAXANT & ANALGESIC CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
INTERNATIONAL PHARMACEUTICAL GENERICS LTD.,
Date of Preparation:
30 Malta Avenue, Suite 2408
February 01, 2010
Brampton, ON
L6Y 4S5
Control#: 135919
2 | P a g e
TABLE
OF CONTENTS
Clinical
Pharmacology..............................................................................................................................3
Indications:................................................................................................................................................7
Contraindications
......................................................................................................................................8
Warnings:..................................................................................................................................................8
Precautions..............................................................................................................................................12
Drug Interactions
....................................................................................................................................13
Adverse Reactions
..................................................................................................................................15
Symptoms and Treatment of
Overdose...................................................................................................17
Dosage and
Administration.....................................................................................................................18
Pharmaceutical
Information....................................................................................................................19
Composition:...........................................................................................................................................21
Availability of Dosage
Forms............